Brind.
  1. Lexaria Bioscience Corp. announced a technical development using DehydraTECH to reduce side effects, while Eli Lilly and Novo Nordisk dominate the obesity drug market.

Lexaria's drug study is underway in Australia and shows superiority over a competitor to STEP's semaglutide.

1 report, 1 independent Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Lexaria's drug study is underway in Australia and shows superiority over a competitor to STEP's semaglutide.

Who's involved

What this event is mainly about
STEP

Keep exploring

Part of

Lexaria Bioscience Corp. announced a technical development using DehydraTECH to reduce side effects, while Eli Lilly and Novo Nordisk dominate the obesity drug market. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ACCESS NewswireLexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTEC